Cidara Therapeutics to Participate in Two Upcoming Investor Conferences
A live audio webcast of the presentation will be available in the Investors section on the Company’s website at www.cidara.com.
|Format:||Panel Discussion - No Fungus Among Us: Addressing an Important Fungal Need|
Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Company’s portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) for the prevention and treatment of influenza and other viral diseases from Cidara’s proprietary Cloudbreak® antiviral platform. Cidara is headquartered in
Karen O’Shea, Ph.D.
Source: Cidara Therapeutics, Inc.